News story

Latest topics referred to NICE: May 2012

This news article was published under the 2010 to 2015 Conservative and Liberal Democrat coalition government

Department of Health ministers agreed to refer the following topics to the National Institute for Health and Clinical Excellence** **(NICE) …

Department of Health ministers agreed to refer the following topics to the National Institute for Health and Clinical Excellence** **(NICE) in May, to begin the process of developing guidance for each topic.

Technology appraisals

The following technology appraisals have been referred to NICE.**

  • To appraise the clinical and cost effectiveness of bortezomib within its licensed indication for induction therapy prior to high dose chemotherapy and autologous stem cell transplantation for the treatment of multiple myeloma.
  • To appraise the clinical and cost effectiveness of bortezomib within its licensed indication for consolidation therapy after autologous stem cell transplantation for the treatment of multiple myeloma.
  • To appraise the clinical and cost effectiveness of canakinumab within its licensed indication for the treatment of systemic juvenile idiopathic arthritis.
  • To appraise the clinical and cost effectiveness of mipomersen, within its licensed indication for the prevention of cardiovascular events in people with homozygous or severe heterozygous familial hypercholesterolemia.
  • To appraise the clinical and cost effectiveness of rivaroxaban within its licensed indication for the prevention of adverse outcomes in patients after the acute management of acute coronary syndrome.
  • To appraise the clinical and cost effectiveness of tofacitinib within its licensed indication for the treatment of rheumatoid arthritis after the failure of disease modifying anti-rheumatic drugs.
  • To appraise the clinical and cost effectiveness of bendamustine in combination with rituximab within its licensed indication for the first-line treatment of mantle cell lymphoma.
  • To appraise the clinical and cost effectiveness of loxapine inhalation for the treatment of acute agitation and disturbed behaviours in people with schizophrenia or bipolar disorder.

Read about NICE technology appraisals on the NICE website.

About NICE referrals

NICE is an independent organisation responsible for providing national guidance on promoting good health and preventing and treating ill health.

Department of Health ministers refer topics to NICE and NICE schedules these topics into its work programme, to begin the process of developing guidance for each topic.

Depending on the type of guidance and its complexity, this can take between 6 months and 2 years.

NICE guidance includes technology appraisals, clinical guidelines, public health guidelines and quality standards.

Find out more about NICE guidance on the NICE website.